CN103052379A - 包含磷酸二酯酶抑制剂的干粉制剂 - Google Patents

包含磷酸二酯酶抑制剂的干粉制剂 Download PDF

Info

Publication number
CN103052379A
CN103052379A CN2011800382903A CN201180038290A CN103052379A CN 103052379 A CN103052379 A CN 103052379A CN 2011800382903 A CN2011800382903 A CN 2011800382903A CN 201180038290 A CN201180038290 A CN 201180038290A CN 103052379 A CN103052379 A CN 103052379A
Authority
CN
China
Prior art keywords
powder according
inhalable
inhalable powder
microns
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800382903A
Other languages
English (en)
Chinese (zh)
Inventor
D·科科尼
F·夏勒蒂
R·比尔兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Priority to CN201710259305.8A priority Critical patent/CN106890165A/zh
Publication of CN103052379A publication Critical patent/CN103052379A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2011800382903A 2010-08-03 2011-07-27 包含磷酸二酯酶抑制剂的干粉制剂 Pending CN103052379A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710259305.8A CN106890165A (zh) 2010-08-03 2011-07-27 包含磷酸二酯酶抑制剂的干粉制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10171748 2010-08-03
EP10171748.6 2010-08-03
PCT/EP2011/062872 WO2012016889A2 (en) 2010-08-03 2011-07-27 Dry powder formulation comprising a phosphodiesterase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710259305.8A Division CN106890165A (zh) 2010-08-03 2011-07-27 包含磷酸二酯酶抑制剂的干粉制剂

Publications (1)

Publication Number Publication Date
CN103052379A true CN103052379A (zh) 2013-04-17

Family

ID=43262631

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800382903A Pending CN103052379A (zh) 2010-08-03 2011-07-27 包含磷酸二酯酶抑制剂的干粉制剂
CN201710259305.8A Pending CN106890165A (zh) 2010-08-03 2011-07-27 包含磷酸二酯酶抑制剂的干粉制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710259305.8A Pending CN106890165A (zh) 2010-08-03 2011-07-27 包含磷酸二酯酶抑制剂的干粉制剂

Country Status (39)

Country Link
US (2) US9132121B2 (enExample)
EP (2) EP3246016B1 (enExample)
JP (1) JP6004233B2 (enExample)
KR (1) KR101805958B1 (enExample)
CN (2) CN103052379A (enExample)
AR (1) AR082443A1 (enExample)
AU (1) AU2011287711B2 (enExample)
BR (1) BR112013002506A2 (enExample)
CA (1) CA2807256C (enExample)
CL (1) CL2013000293A1 (enExample)
CO (1) CO6690744A2 (enExample)
CY (1) CY1120605T1 (enExample)
DK (2) DK2600830T3 (enExample)
EA (2) EA024922B1 (enExample)
ES (2) ES3033142T3 (enExample)
FI (1) FI3246016T3 (enExample)
GE (1) GEP20156343B (enExample)
HR (2) HRP20180717T1 (enExample)
HU (2) HUE071256T2 (enExample)
IL (1) IL224517B (enExample)
LT (2) LT3246016T (enExample)
MA (1) MA34449B1 (enExample)
ME (1) ME03022B (enExample)
MX (1) MX346424B (enExample)
MY (1) MY179703A (enExample)
NO (1) NO2600830T3 (enExample)
NZ (1) NZ606548A (enExample)
PE (2) PE20171256A1 (enExample)
PH (1) PH12013500235A1 (enExample)
PL (2) PL2600830T3 (enExample)
PT (2) PT2600830T (enExample)
RS (2) RS57061B1 (enExample)
SG (1) SG187258A1 (enExample)
SI (2) SI3246016T1 (enExample)
SM (1) SMT202500256T1 (enExample)
TR (1) TR201807012T4 (enExample)
UA (1) UA112296C2 (enExample)
WO (1) WO2012016889A2 (enExample)
ZA (1) ZA201300870B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
KR101803121B1 (ko) 2010-08-03 2017-11-29 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제를 포함하는 약학적 제제
WO2012168226A1 (en) 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
EP2968204B1 (en) * 2013-03-15 2019-05-15 Robert I. Henkin Phosphodiesterase inhibitors for treating taste and smell disorders
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
RS61558B1 (sr) 2013-10-22 2021-04-29 Chiesi Farm Spa Kristalni oblik pde4 inhibitora
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
US20180021256A1 (en) 2014-07-09 2018-01-25 Arven Ilac Sanayi Ve Ticaret A.S. Process for the preparation of formulations for inhalation
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
US12569493B2 (en) 2020-03-24 2026-03-10 Cyrano Therapeutics Inc. Treatment of chemosensory dysfunction from a coronavirus infection
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
WO2023208982A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Crystal form of a pde4 inhibitor
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
CA3268243A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR
CA3268102A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR
KR20250069949A (ko) 2022-09-22 2025-05-20 키에시 파르마슈티시 엣스. 피. 에이. 포스포다이에스테라제-4 억제제의 투여를 위한 캡슐 흡입기

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1424909A (zh) * 2000-04-17 2003-06-18 维克多瑞有限公司 吸入器装置中使用的制剂
WO2009018909A2 (en) * 2007-08-08 2009-02-12 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19841248A1 (de) 1997-09-12 1999-04-29 Fraunhofer Ges Forschung Demonstrationseinrichtung in Form eines Lebewesens
DE59801018D1 (de) 1997-09-16 2001-08-16 Trench Switzerland Ag Basel Spannungsteiler
PL196951B1 (pl) 1999-03-05 2008-02-29 Chiesi Farma Spa Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika
IL153705A0 (en) 2000-06-27 2003-07-06 Vectura Ltd Method of making particles for use in a pharmaceutical composition
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
PT1386630E (pt) 2002-07-31 2006-09-29 Chiesi Farma Spa Inalador em po
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
CA2608837C (en) * 2005-06-06 2011-08-02 F. Hoffmann-La Roche Ag Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l-cpt1) inhibitors
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2070913A1 (en) * 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
KR101803121B1 (ko) 2010-08-03 2017-11-29 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제를 포함하는 약학적 제제
WO2012168226A1 (en) 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
RS61558B1 (sr) 2013-10-22 2021-04-29 Chiesi Farm Spa Kristalni oblik pde4 inhibitora

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1424909A (zh) * 2000-04-17 2003-06-18 维克多瑞有限公司 吸入器装置中使用的制剂
WO2009018909A2 (en) * 2007-08-08 2009-02-12 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法

Also Published As

Publication number Publication date
ME03022B (me) 2018-10-20
EA201390049A1 (ru) 2013-05-30
ES2664175T3 (es) 2018-04-18
EP2600830B1 (en) 2018-02-21
PT2600830T (pt) 2018-04-02
DK2600830T3 (en) 2018-03-12
ES3033142T3 (en) 2025-07-31
ZA201300870B (en) 2014-04-30
GEP20156343B (en) 2015-08-10
LT2600830T (lt) 2018-04-10
MX2013001172A (es) 2013-03-07
DK3246016T3 (da) 2025-05-19
PE20171256A1 (es) 2017-08-28
CL2013000293A1 (es) 2013-05-03
PH12013500235A1 (en) 2016-05-25
CA2807256C (en) 2018-08-28
NZ606548A (en) 2015-02-27
AR082443A1 (es) 2012-12-05
LT3246016T (lt) 2025-05-26
RS57061B1 (sr) 2018-06-29
PT3246016T (pt) 2025-06-25
BR112013002506A2 (pt) 2016-05-31
WO2012016889A2 (en) 2012-02-09
IL224517B (en) 2018-04-30
CY1120605T1 (el) 2019-12-11
PL2600830T3 (pl) 2018-08-31
EP3246016B1 (en) 2025-04-09
AU2011287711A1 (en) 2013-02-21
MA34449B1 (fr) 2013-08-01
AU2011287711B2 (en) 2016-10-27
MX346424B (es) 2017-03-21
KR101805958B1 (ko) 2017-12-07
HUE037620T2 (hu) 2018-09-28
UA112296C2 (uk) 2016-08-25
EP2600830A2 (en) 2013-06-12
CA2807256A1 (en) 2012-02-09
US20150342936A1 (en) 2015-12-03
JP2013532705A (ja) 2013-08-19
EA024922B1 (ru) 2016-11-30
US9132121B2 (en) 2015-09-15
MY179703A (en) 2020-11-11
SMT202500256T1 (it) 2025-09-12
US20120031403A1 (en) 2012-02-09
WO2012016889A3 (en) 2012-04-19
NO2600830T3 (enExample) 2018-07-21
EA027692B1 (ru) 2017-08-31
EP3246016A1 (en) 2017-11-22
FI3246016T3 (fi) 2025-07-08
HRP20250711T1 (hr) 2025-08-15
JP6004233B2 (ja) 2016-10-05
US9308200B2 (en) 2016-04-12
CN106890165A (zh) 2017-06-27
KR20130094784A (ko) 2013-08-26
CO6690744A2 (es) 2013-06-17
PL3246016T3 (pl) 2025-06-16
SI2600830T1 (en) 2018-05-31
EA201690541A1 (ru) 2016-07-29
PE20130601A1 (es) 2013-05-30
SI3246016T1 (sl) 2025-06-30
SG187258A1 (en) 2013-03-28
TR201807012T4 (tr) 2018-06-21
HRP20180717T1 (hr) 2018-07-13
HUE071256T2 (hu) 2025-08-28
RS66876B1 (sr) 2025-07-31

Similar Documents

Publication Publication Date Title
CN103052379A (zh) 包含磷酸二酯酶抑制剂的干粉制剂
CN102946868B (zh) 包含抗毒蕈碱药的干粉制剂
US20090192187A1 (en) Dry powder formulation comprising an anticholinergic drug
CA2951483C (en) Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
EP3621589B1 (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
HK1239571A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
HK1182002A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
HK1182000A (en) Dry powder formulation comprising an antimuscarinic drug
HK1232434A1 (en) Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1182002

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20130417

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1182002

Country of ref document: HK